1.Stein AN, et al. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009; 27: 520–529.
2.MacIntyre CR, et al. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiology and Infection 2003; 131: 675–682.
3.Carapetis JR, et al. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine 2004; 23: 755–761.
4.Brotherton J, et al. Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Communicable Diseases Intelligence 2004; 28 (Suppl. 2): vii-S116.
5.Vally H, et al. An outbreak of chickenpox at a child care centre in Western Australia. Costs to the community and implications for vaccination policy. Australian and New Zealand Journal of Public Health 2007; 31: 113–119.
6.Chant KG, et al. Varicella-zoster virus infection in Australia. Australian and New Zealand Journal of Public Health 1998; 22: 413–418.
7.Nguyen HQ, et al. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. New England Journal of Medicine 2005; 352: 450–458.
8.Zhou F, et al. Impact of varicella vaccination on health care utilization. Journal of the American Medical Association 2005; 294: 797–802.
9.Seward JF, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. Journal of the American Medical Association 2002; 287: 606–611.
10.Davis MM, et al. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004; 114: 786–792.
11.Jumaan AO, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. Journal of Infectious Diseases 2005; 191: 2002–2007.
12.Hope-Simpson RE. Nature of herpes zoster – a long-term study and a new hypothesis. Proceedings of the Royal Society of Medicine 1965; 58: 9–20.
13.Brisson M, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500–2507.
14.Solomon BA, et al. Lasting immunity to varicella in doctors study (L.I.V.I.D. study). Journal of the American Academy of Dermatology 1998; 38: 763–765.
15.Thomas SL, et al. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678–682.
16.Brisson M, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiology and Infection 2000; 125: 651–669.
17.Brisson M, et al. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. Journal of Medical Virology 2003; 70(Suppl. 1): S31–S37.
18.Schuette MC, Hethcote HW. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bulletin of Mathematical Biology 1999; 61: 1031–1064.
19.Garnett GP, Grenfell BT. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiology and Infection 1992; 108: 513–528.
20.Mullooly JP, et al. Incidence of herpes zoster, 1997–2002. Epidemiology and Infection 2005; 133: 245–253.
21.Yih WK, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005; 5: 68.
22.Yawn BP, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proceedings 2007; 82: 1341–1349.
23.Patel MS, et al. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infection Control and Hospital Epidemiology 2008; 29: 1157–1163.
24.Civen R, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatric Infectious Disease Journal 2009; 28: 954–959.
25.Gidding HF, et al. Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. Australian and New Zealand Journal of Public Health 2005; 29: 544–551.
26.Gao Z, et al. Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiology and Infection 2010; 138: 457–468.
27.Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 2271–2284.
28.Cunningham AL, et al. The prevention and management of herpes zoster. Medical Journal of Australia 2008; 188: 171–176.
29.Garnett GP, Ferguson NM. Predicting the effect of varicella caccine on subsequent cases of zoster and varicella. Reviews in Medical Virology 1996; 6: 151–161.
30.Australian Bureau of Statistics. Population by age and sex, Australian states and territories, JunE 2008. Canberra, 2008.
31.Hull B, et al. Immunisation coverage annual report, 2007. Communicable Diseases Intelligence 2009; 33: 170–187.
32.Macartney KK, et al. Varicella vaccination in Australia. Journal of Paediatrics and Child Health 2005; 41: 544–552.
33.Gilbert GL, et al. Varicella seroprevalence and vaccine uptake in preschool children. Medical Journal of Australia 2005; 182: 42.
34.Marshall H, et al. Uptake of varicella vaccine – a cross sectional survey of parental attitudes to nationally recommended but unfunded varicella immunisation. Vaccine 2005; 23: 5389–5397.
35.Marshall H, et al. Varicella immunisation practice: Implications for provision of a recommended, non-funded vaccine. Journal of Paediatrics and Child Health 2009; 45: 297–303.
36.Miller ER, Kelly HA. Varicella infection – evidence for peak activity in summer months. Journal of Infection 2008; 56: 360–365.
37.Zak-Prelich M, et al. The role of solar ultraviolet irradiation in zoster. Epidemiology and Infection 2002; 129: 593–597.
38.Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infectious Diseases 2004; 4: 26–33.